Emd Serono Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EMD SERONO INC, and when can generic versions of EMD SERONO INC drugs launch?
EMD SERONO INC has six approved drugs.
There are thirteen US patents protecting EMD SERONO INC drugs.
There are one hundred and ninety-five patent family members on EMD SERONO INC drugs in forty-two countries and eighty-nine supplementary protection certificates in sixteen countries.
Summary for Emd Serono Inc
| International Patents: | 195 |
| US Patents: | 13 |
| Tradenames: | 6 |
| Ingredients: | 5 |
| NDAs: | 6 |
| Drug Master File Entries: | 2 |
Drugs and US Patents for Emd Serono Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-001 | Aug 11, 2000 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-002 | Aug 11, 2000 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Emd Serono Inc | GLUCOPHAGE | metformin hydrochloride | TABLET;ORAL | 020357-002 | Mar 3, 1995 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-001 | Sep 26, 1997 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Emd Serono Inc | GLUCOPHAGE | metformin hydrochloride | TABLET;ORAL | 020357-003 | Nov 5, 1998 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | 8,658,643 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Emd Serono Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-001 | Aug 11, 2000 | 6,319,192 | ⤷ Try a Trial |
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-002 | Sep 26, 1997 | 4,517,181 | ⤷ Try a Trial |
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-001 | Sep 26, 1997 | 4,517,181 | ⤷ Try a Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-002 | Aug 11, 2000 | 4,800,191 | ⤷ Try a Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-002 | Aug 11, 2000 | 6,319,192 | ⤷ Try a Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-002 | Aug 11, 2000 | 6,863,891 | ⤷ Try a Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-001 | Aug 11, 2000 | 5,198,533 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Emd Serono Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3332789 | ⤷ Try a Trial |
| European Patent Office | 2272503 | ⤷ Try a Trial |
| Japan | 6430554 | ⤷ Try a Trial |
| China | 101687857 | ⤷ Try a Trial |
| Poland | 2164844 | ⤷ Try a Trial |
| Hong Kong | 1145265 | ⤷ Try a Trial |
| Spain | 2428741 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Emd Serono Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2805723 | PA2018503 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: KLADRIBINAS; REGISTRATION NO/DATE: EU1/17/1212/001-006 20170822 |
| 1608344 | C20180007 00334 | Estonia | ⤷ Try a Trial | PRODUCT NAME: KLADRIBIIN;REG NO/DATE: EU/1/17/1212 24.08.2017 |
| 1608344 | LUC00065 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: CLADRIBINE; AUTHORISATION NUMBER AND DATE: EU/1/17/1212 20170824 |
| 0299402 | 099C0031 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ACETATE DE CETRORELIX; REGISTRATION NO/DATE: EU/1/99/100/001 19990413 |
| 2164843 | 2290029-4 | Sweden | ⤷ Try a Trial | PRODUCT NAME: TEPOTINIB AND PHARMACEUTICALLY USABLE SOLVATES, SALTS, AND TAUTOMERS THEROF; REG. NO/DATE: EU/1/21/1596 20220217 |
| 0299402 | 31/1999 | Austria | ⤷ Try a Trial | PRODUCT NAME: CETRORELIX UND PHARMAZEUTISCH ANNEHMBARE SAEUREADDITIONSSALZE DAVON, INSBESONDERE CETRORELIXACETAT; REGISTRATION NO/DATE: EU/1/99/100/001- EU/1/99/100/003 19990413 |
| 1608344 | C 2018 010 | Romania | ⤷ Try a Trial | PRODUCT NAME: CLADRIBINA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1212; DATE OF NATIONAL AUTHORISATION: 20170822; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1212; DATE OF FIRST AUTHORISATION IN EEA: 20170822 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
